V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10455491 | 10042108 | 1.78 | 72.7 | Palliative (P) | 2018-09-15 | 2018-09-16 | Methotrexate intrathecal | 02 | N | RIALTO TRIAL | 100792335 |
| 10455582 | 10042109 | 1.65 | 78.6 | 03 | 2019-06-12 | 2019-06-23 | CHLVPP | N | N | MELPHALAN | 101346254 |
| 10455599 | 10042110 | 1.75 | null | Curative (C) | 2018-04-12 | 2018-05-04 | Doxorubicin chemoembolisation | 2 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 101486861 |
| 10455942 | 10042114 | 1.83 | 88.4 | Palliative (P) | 2018-09-02 | 2018-09-03 | Bortezomib + Panobinostat | 01 | N | IXAZOMIB + LENALIDOMIDE | 100478810 |
| 10455948 | 10042115 | 1.77 | 96 | Neo-adjuvant (N) | 2017-12-03 | 2017-12-04 | null | 01 | null | PLATO TRIAL | 100928973 |
| 10455994 | 10042116 | 1.84 | 75 | Disease modification (D) | 2019-01-02 | 2019-01-04 | CHLORAMBUCIL + OFATUMUMAB | 02 | Y | DOXORUBICIN EMBOLISATION | 100057804 |
| 10456094 | 10042118 | 1.77 | 80 | null | 2021-12-30 | 2022-01-22 | Doxorubicin chemoembolisation | 02 | null | LUTETIUM-177 | 100470356 |
| 10456152 | 10042119 | 1.7 | null | Palliative (P) | 2019-01-07 | 2019-01-18 | Tivozanib | 02 | null | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 101823908 |
| 10456186 | 10042120 | 1.74 | 70.9 | 03 | 2019-04-12 | 2019-05-09 | GemCarbo Days 1+8 | 02 | null | MYELOMA XII TRIAL | 100520601 |
| 10456315 | 10042121 | 1.5 | 44 | Adjuvant (A) | 2019-12-17 | 2020-02-11 | Doxorubicin + Olaratumab | N | N | FEC | 100751880 |
| 10456439 | 10042122 | 1.57 | 69.8 | Palliative (P) | 2018-07-12 | 2018-07-24 | ABVD | 02 | N | FEC + DOCETAXEL | 100793740 |
| 10456500 | 10042123 | 1.7 | 68.8 | Neo-adjuvant (N) | 2019-06-07 | 2019-06-20 | IDELALISIB + RITUXIMAB | N | null | BLEOMYCIN | 101412367 |
| 10456506 | 10042124 | 1.64 | null | Palliative (P) | 2017-11-09 | 2017-11-09 | Melphalan IV High dose | 02 | N | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 101217331 |
| 10456714 | 10042127 | 1.72 | 105 | null | 2019-11-07 | 2019-11-07 | Letrozole + Palbociclib | 02 | N | PETREA TRIAL | 100010540 |
| 10456759 | 10042128 | 1.8 | 60.6 | Curative (C) | null | 2019-01-23 | Capecitabine (21days) + Carboplatin | N | N | IRINOTECAN | 101132474 |
| 10456807 | 10042130 | 1.95 | 95.5 | null | 2019-02-16 | 2019-02-16 | Everolimus 10mg | 02 | null | CABAZITAXEL | 101200136 |
| 10456923 | 10042131 | 1.42 | 64.1 | Palliative (P) | 2020-03-21 | 2020-03-21 | IDELALISIB + RITUXIMAB | 02 | N | BINIMETINIB + ENCORAFENIB | 100001107 |
| 10457081 | 10042132 | 1.64 | 78.35 | null | 2019-11-28 | 2019-12-10 | Capecitabine (14 days)+Carboplatin | 02 | null | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 101822764 |
| 10457108 | 10042133 | 1.63 | 57.5 | 03 | null | 2020-08-20 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | null | MUK 6 TRIAL | 100683022 |
| 10457185 | 10042135 | 1.71 | 50.8 | Palliative (P) | 2018-09-11 | 2018-09-11 | ECX | 02 | N | BORTEZOMIB + PANOBINOSTAT | 101304930 |
| 10457264 | 10042136 | 1.68 | 91.2 | Adjuvant (A) | 2021-04-24 | 2021-05-23 | null | N | null | CAPECITABINE + RT | 100644906 |
| 10457276 | 10042137 | 1.66 | 76 | Curative (C) | 2017-04-10 | 2017-04-24 | CAPECITABINE + CARBOPLATIN | 02 | null | AML18 TRIAL | 100101604 |
| 10457463 | 10042139 | 1.72 | 67.4 | Disease modification (D) | 2017-04-01 | 2017-04-07 | null | N | N | ATEZOLIZUMAB | 101639886 |
| 10457480 | 10042140 | 1.62 | 96.45 | null | 2018-05-24 | 2018-05-31 | Letrozole + Palbociclib | N | Y | LETROZOLE + PALBOCICLIB | 100480975 |
| 10457637 | 10042142 | 1.68 | 56.8 | Curative (C) | 2019-09-20 | 2019-09-26 | CABOZANTINIB | 2 | null | CAPECITABINE + CARBOPLATIN | 100578140 |
| 10457638 | 10042143 | 1.7 | 83.6 | null | 2021-11-20 | 2021-11-26 | CVP | 02 | null | LENALIDOMIDE + RITUXIMAB | 100595786 |
| 10457652 | 10042144 | 1.63 | 0 | Neo-adjuvant (N) | 2019-11-14 | 2019-11-15 | SAPROCAN TRIAL | 02 | null | RITUXIMAB + VENETOCLAX | 100893378 |
| 10457867 | 10042146 | 0 | null | Curative (C) | 2020-03-06 | 2020-03-08 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 02 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100435008 |
| 10458023 | 10042150 | null | 82 | Curative (C) | 2019-03-11 | 2019-03-19 | EOX | 01 | N | TRANSPLANT ANTI-THYMOCYTE GLOBULIN + BUSULFAN + FLUDARABINE | 100801840 |
| 10458058 | 10042151 | 1.85 | 67.3 | Disease modification (D) | 2020-02-28 | 2020-03-04 | Carboplatin + Liposomal Doxorubicin | 02 | null | CISPLATIN + CAPECITABINE + EPIRUBICIN | 101288041 |
| 10458219 | 10042155 | 1.67 | 89 | null | 2020-06-18 | 2020-07-08 | CAPECITABINE + RT | 02 | null | CHLORAMBUCIL + PROCARBAZINE + VINBLASTINE | 100775748 |
| 10458316 | 10042156 | 1.63 | 101.75 | Neo-adjuvant (N) | 2018-09-25 | 2018-09-29 | GEMCITABINE + PACLITAXEL ALBUMIN (ABRAXANE) | N | N | STAMPEDE TRIAL | 101136282 |
| 10458341 | 10042158 | 1.72 | 69.6 | null | 2021-03-30 | 2021-03-30 | MPT | 02 | null | ALEMTUZUMAB | 101035248 |
| 10458588 | 10042161 | null | null | Palliative (P) | 2019-02-15 | 2019-02-20 | THALIDOMIDE | Y | null | BORTEZOMIB + DARATUMUMAB | 101193983 |
| 10458629 | 10042162 | 1.73 | 84.5 | null | 2019-07-29 | 2019-08-01 | GEMCITABINE + PACLITAXEL ALBUMIN (ABRAXANE) | 02 | N | UKALL60+ | 100675885 |
| 10458667 | 10042163 | 1.84 | 66 | 03 | 2019-04-24 | 2019-04-24 | Bortezomib + Panobinostat | 02 | null | CISPLATIN + PEMETREXED | 101281847 |
| 10458723 | 10042164 | 1.6 | 0 | Disease modification (D) | 2019-07-16 | 2019-07-17 | Cisplatin + Etoposide po&iv 3 day | 02 | Y | LETROZOLE + PALBOCICLIB | 101164968 |
| 10459331 | 10042166 | 1.6 | 96 | null | 2021-03-30 | 2021-04-06 | EOX | 02 | null | RIALTO TRIAL | 100769524 |
| 10459358 | 10042167 | 1.68 | 73.3 | Curative (C) | 2018-02-20 | 2018-03-09 | DABRAFENIB | 02 | null | APALUTAMIDE | 101133889 |
| 10459494 | 10042168 | 1.81 | 87 | Palliative (P) | 2020-01-09 | 2020-01-19 | Irinotecan + Modified De Gramont | 02 | N | ELOQUENT2 TRIAL | 100968597 |
| 10459592 | 10042169 | 1.73 | 82.8 | 03 | 2019-10-17 | 2019-10-17 | null | 02 | N | FCR | 101277106 |
| 10459636 | 10042170 | null | 92.9 | Palliative (P) | null | 2021-04-04 | CARBOPLATIN + EPIRUBICIN | N | null | OBINUTUZUMAB + VENETOCLAX | 101531292 |
| 10459673 | 10042171 | 0 | 80.6 | Curative (C) | null | 2019-08-10 | DA 3 + 10 | 02 | N | BORTEZOMIB + DARATUMUMAB | 100515397 |
| 10459690 | 10042172 | 0 | 60.7 | Neo-adjuvant (N) | 2020-03-03 | 2020-03-07 | Cape+Cisplatin+Trastuzumab Load | 02 | N | EVEROLIMUS | 101226327 |
| 10459767 | 10042175 | 1.68 | 54.4 | Curative (C) | 2019-03-23 | 2019-04-12 | GEMCITABINE + NAB PACLITAXEL | 02 | N | GEMCARBO | 100540598 |
| 10460144 | 10042179 | 1.58 | 89.3 | Adjuvant (A) | null | 2018-04-14 | Capecitabine + Carboplatin + RT | N | Y | INCA TRIAL | 101533449 |
| 10460258 | 10042181 | 1.67 | 115 | 03 | 2014-07-09 | 2017-07-01 | null | 02 | null | OCTREOTIDE | 101807638 |
| 10460308 | 10042182 | 1.73 | 76 | null | 2019-05-26 | 2019-05-26 | TALIMOGENE LAHERPAREPVEC | 02 | null | ATEZOLIZUMAB + BEVACIZUMAB | 101674381 |
| 10460412 | 10042184 | 0 | 65 | null | 2022-04-07 | 2022-04-19 | CETUXIMAB | 02 | null | ABEMACICLIB + FULVESTRANT | 101301221 |
| 10460442 | 10042185 | 1.72 | 76.3 | Palliative (P) | 2018-06-06 | 2018-06-21 | OSIMERTINIB | null | N | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 101781268 |